Connect to other sites within the UBM Medica Network
Selumetinib may become a treatment option for stage III/IV differentiated thyroid cancer. Image © Nerthuz/Shutterstock.com
Driver Mutations, Tumor Diameter Prognostic in Tumors of the Eye
Along with gene expression signatures from a 15-loci panel, tumor diameter and specific driver mutations predict metastasis risk and survival among patients with uveal melanoma.
Cabozantinib Improves Survival in Patients With Previously Treated RCC
Compared to everolimus, the oral tyrosine kinase inhibitor cabozantinib improves objective tumor response, delays disease progression, and prolongs overall survival time among patients with RCC.
Pembrolizumab Yields Strong Long-Term Survival in Advanced Melanoma
In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
Rheumatic Adverse Events Reported for Patients Treated with Nivolumab, Ipilimumab
Inflammatory arthritis and sicca syndrome appear to be immune-related adverse events among some patients undergoing cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab.
Inotuzumab Ozogamicin May Benefit Patients With Acute Lymphoblastic Leukemia
Researchers published a study June 12, 2016, in the online issue of The New England Journal of Medicine that suggests progression-free survival and overall survival may both be longer with inotuzumab ozogamicin in ALL.
ASCO 2016: Phase I Trial Results With Vorinostat in Head and Neck Cancer
In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
Molecular Imaging of Tumor Metabolism Predicts Lung Cancer Response to Immunotherapy
Molecular imaging of tumor glucose metabolism might be a prognostic biomarker of NSCLC responses to the investigational immunotherapy agent atezolizumab.
March 2016 News Recap
In case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
Epidermal Growth Factor Receptor Inhibitor Cutaneous Side Effects
This slide show highlights some of the cutaneous side effects related to the use of epidermal growth factor receptor inhibitors (EGFRI).
Slide Show: Highlights From the 2015 ASCO Breast Cancer Symposium
This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.
Slide Show: Trends in Targeted Therapies and Immunotherapies
This slide show provides information on the present and future of targeted therapies and immunotherapies based on a report from the IMS Institute for Healthcare Informatics.
By clicking Accept, you agree to become a member of the UBM Medica Community.